Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
about
Voriconazole therapeutic drug monitoring.Ventilator-associated pneumonia: diagnosis, treatment, and preventionDose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsApplication of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiConcentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyPharmacokinetics of gatifloxacin in infants and childrenA clinical pathway for community-acquired pneumonia: an observational cohort studyPharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Ciprofloxacin dosage and emergence of resistance in human commensal bacteriaAntimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.Clinical practice guideline (update): adult sinusitis.Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamPharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.Population pharmacokinetic model for gatifloxacin in pediatric patients.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Setting and revising antibacterial susceptibility breakpoints.Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics.Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists.Pharmacodynamics of antimicrobials: treatment optimisation.Levofloxacin for the treatment of community-acquired pneumonia.The use of fluoroquinolones in children: recent advances.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.
P2860
Q24542411-B5A2F86B-CA80-4FE9-B4DD-6482AE9330E9Q29012676-93EA3DB6-AE20-44B9-99AB-F7112CADCCF4Q33571422-B018AC86-AC10-4A77-B128-CA38CD09CE0DQ33767602-D9891AE5-EF1F-4E76-BB8C-1DA492DBAA1FQ33769931-D3DB53C2-73B8-4EA6-8EF2-FD452B49ED0EQ33819854-6472AF75-0642-4F54-8EEA-CDD4E642F4B8Q33827819-B0914D06-41A8-42C8-9F6E-BA5706086A56Q33856763-1274E96D-6B98-4D14-8641-36E5090C3A7BQ33953008-37FA70CE-9496-4F80-BF54-D9A4C10DD1C3Q34057534-813542E6-E48C-4E8E-B112-B7B49632C918Q34077003-94050EBF-A4CE-4085-9D7F-67DF32BEE04AQ34104262-86096C83-1568-430C-8986-79B53F0E327AQ34188814-3622776E-B4CD-4E8F-B6B4-538904A4E406Q34274190-3839035C-4412-4D3D-A954-6268B3D807A1Q34278283-016F1EDA-BD02-4763-90E3-4B1E87E8775DQ34307105-E79849DB-B623-495D-8863-ADF040AA1B81Q34469863-D654A570-D767-4E33-8BE2-2597E7D7A0CEQ34509676-FD7DC047-C27F-4976-94D4-18308B3ADA26Q34725279-E4568A8C-6AAF-43C9-B900-1F7ACBC0D4E2Q35065775-70BD99E2-61AF-4CF3-BEB7-3502BE917B5EQ35139545-ACD9519D-C02F-4197-8E1D-266FF79028CCQ35168927-3E91DD00-A215-4268-AFE7-7E692F61A637Q35547236-D4EEB30D-DC6C-44FF-BFE1-3E39FF452DAAQ35685485-62B42923-41CD-4DC1-973F-DC0799E55528Q35758967-C442119A-0A03-43B8-A662-5268A397F38CQ35759054-B4A05399-AC54-4CDB-88FE-A69281FB38ADQ35840772-CB00DCD9-4B86-4260-80F1-11E1A2160EC6Q35913176-4A708B32-49F1-479C-ACE8-B1CF41DAA14EQ35917230-3A5F3870-4813-4323-A8EB-E768C313DC81Q36021991-93BDB984-4C02-48E7-9D9D-13C84531BB8DQ36083619-CA8A0F7E-4135-4B5D-B4BE-80FB2B376257Q36161246-4525D2D8-A736-4880-8524-0D772003D323Q36162355-9C4DA399-3217-4E31-8D7B-E6475E2DBC95Q36313211-313090B2-3062-409B-AE05-60365B7BF06AQ36320613-81B7C15A-66AC-4F0F-A7A1-834D0BDAA76FQ36408747-F54B9AB3-28CC-4C83-8D04-61F63B3C03B7Q36544935-3B0517A3-3A1F-43F6-B27A-0C53C46B4727Q36670872-43CD2B9D-C860-401A-A86F-8140BECCB7EEQ36670907-3B2C2862-AE02-4EBF-8815-335A7A358FC1Q36777850-6F694D7B-9D35-4E5E-BCB2-470CDC9C2B7B
P2860
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@ast
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@en
type
label
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@ast
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@en
prefLabel
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@ast
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@en
P2093
P2860
P1476
Pharmacodynamics of fluoroquin ...... respiratory tract infections.
@en
P2093
D M Grasela
J Passarell
P F Pierce
P G Ambrose
T H Grasela
P2860
P304
P356
10.1128/AAC.45.10.2793-2797.2001
P407
P577
2001-10-01T00:00:00Z